Nightingale Health Plc
Company release
Inside information
27 November 2024 at 2:20 p.m. (EET)

The Board of Directors of Nightingale Health Plc ("Nightingale Health"), a pioneer in disease risk detection and preventative health, has decided to investigate the possible transfer of the company's publicly traded series B shares (the "Shares") from Nasdaq First North Growth Market Finland to the main market of Nasdaq Helsinki Ltd (the "Main Market") and the possible cross-trading of the Shares on the OTCQX market, managed by the OTC Markets Group Inc. ("OTC Markets") in the United States.

The transfer to the Main Market and the cross-trading of the Shares on the OTCQX market could take place during the first half of 2025. As Nightingale Health has a strong financial position, it is not considering issuing new shares in connection with the potential transfer.

Nightingale Health's Shares have been listed on the Nasdaq First North Growth Market Finland since March 2021. In 2022, Nightingale Health adopted the International Financial Reporting Standards (IFRS) and reports financial information in accordance with the IFRS, which is one of the requirements for companies listed on the Main Market.

The aim of the possible transfer to the Main Market in Finland and entry to the OTCQX market in the United States is to improve the liquidity of the Shares and to achieve a broader international shareholder base. 

OTC Markets operates the U.S. equity market for securities not listed on a national exchange. The benefit of OTC market is that shares become tradeable to all U.S. investors and that the process of joining the OTC market is simple and cost-effective. The OTCQX is the highest quality tier of OTC Markets.

"We have made great progress with our strategy during the years as a First North listed company - Nightingale Health's technology is already used in nationwide primary healthcare in Finland covering approximately 30% of Finland's working population and we are also making rapid progress in adopting our technology in healthcare in Singapore, United Kingdom and the United States. In addition to the commercial success, we have demonstrated strong capital markets performance, evidenced by having the best share price performance Year To Date 2024 out of all Finnish listed companies at more than +110%, and by being amongst the top three most traded companies in Nasdaq First North Growth Market Finland." says Teemu Suna, CEO and Founder of Nightingale Health.

"As we continue to pursue growth globally, we consider the possible transfer to the Main Market as a natural next step on our journey. We have agreed several strong partnerships especially in the United States and are building a local laboratory to support these and other future initiatives. Main Market combined with the OTC dual quotation aligns very well with the current stage of Nightingale Health and we see now is the right time to make the transfer" Suna continues.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Its data-driven disclosure standards form the foundation of its three public markets: OTCQX® Best Market, OTCQB® Venture Market and Pink® Open Market.

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

Certified advisor:

Oaklins Finland Ltd, tel. +358 9 6129 670

About Nightingale Health

Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world's most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale's Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company's Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com/